 CAMBRIDGE, Mass., May 19, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq:RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting aAPC cell program, RTX-321, at the American Society of Clinical Oncology ASCO Annual Meeting being held virtually from June 4-8, 2021. 